CCN2 and rheumatoid arthritis: By contrast, to antagonize CTGF for therapeutic purposes, an antibody is mainly used for antifibrosis while missed in RA treatment, to say nothing of its major disadvantages in terms of immunogenicity, unsatisfactory storage, and long-term exploitation (17–19).